Theoretically, anti-angiogenic drugs can be maintained for a long time if they are effective. If resistance develops during maintenance use and the tumor progresses, it needs to be discontinued and replaced with another treatment. If intolerable toxicity occurs, the drug should be discontinued even if it is effective. If the patient’s financial condition does not allow, the drug can only be discontinued. After all, anti-angiogenic drugs are more expensive than conventional chemotherapy drugs. When applying anti-angiogenic drugs, the most important point is to monitor the vascular status of tumor cells at all times and assess whether the tumor is in the awakened or dormant state. If the tumor shows signs of recurrence, early action should be taken or the treatment regimen should be changed or other drugs should be added along with the anti-angiogenic drugs.